The United States Food and Drug Administration (FDA) has significantly evolved its regulatory framework for generic drug development over recent years, introducing new guidance documents, streamlined pathways, and enhanced scientific standards. This review examines the FDA’s current expectations for generic product development, focusing on bioequivalence requirements, complex generic formulations, quality standards, and emerging regulatory pathways. Key developments include the expansion of alternative bioequivalence approaches, enhanced guidance for complex products, implementation of the Generic Drug User Fee Amendments (GDUFA III), and increased focus on pharmaceutical quality metrics. This article provides a comprehensive analysis of these developments and their implications for generic drug manufacturers navigating the current regulatory landscape.
Association for Accessible Medicines. 2024 Generic drug & biosimilars access and savings in the U.S. report. AAM, 2024.
2.
FDA. Generic Drug User Fee Amendments Reauthorization (GDUFA III). Commitment letter. FDA, 2022.
3.
Federal Register. Generic drug user fee amendments of 2022. Fed Regist2022; 87(198): 62451–62489.
4.
FDA. Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA, 2021.
5.
FDA. Guidance for industry: assessing the effects of food on drugs in INDs and NDAs — clinical pharmacology considerations. FDA, 2022.
6.
FDA. Draft guidance: population pharmacokinetics. FDA, 2020.
7.
ZhangXYangYGrimsteinM, et al.Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions. J Clin Pharmacol2020; 60: S160–S178. https://doi.org/10.1002/jcph.1767
8.
FDA. Guidance for industry: locally acting drug products: quality, efficacy, and safety considerations. FDA, 2023.
LionbergerRARawASKimSH, et al.Alternative bioequivalence approaches for complex generic drug products. Clin Pharmacol Ther2023; 113(4): 758–767.
11.
FDA. Draft guidance: bioequivalence recommendations for specific orally inhaled drug products. FDA, 2023.
12.
NewmanSPChanHK. In Vitro–In vivo correlations for drugs delivered by inhalation. Pharm Res2023; 40: 2615–2629.
13.
ZhaoLKimMJZhangL, et al.Quantitative analyses of physiologically based pharmacokinetic model submission to support regulatory decision making. Clin Pharmacol Ther2023; 114(1): 98–106.
14.
FDA. Guidance for industry: the use of physiologically based pharmacokinetic analyses — biopharmaceutics applications for oral drug product development. FDA, 2023.
15.
HeimbachTKesisoglouFNovakovicJ, et al.PBPK modeling to support waivers of in vivo clinical studies. Pharm Res2023; 40: 1833–1851.
16.
FDA. Manual of policies and procedures: MAPP 5240.3 Rev.3 prioritization of the review of ANDAs. FDA, 2022.
17.
FDA. Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin. FDA, 2021.
18.
BurgessDJCrommelinDJAHussainAS, et al.Assuring quality and performance of complex parenteral products. AAPS J2024; 26: 15.
19.
MartinezMNMochelJPNeuhoffS, et al.Physiologically based pharmacokinetic modeling for drug development and regulatory science. J Pharm Sci2023; 112(1): 32–43.
20.
FDA. Guidance for industry: comparative analyses and related comparative use human factors studies for drug-device combination products. FDA, 2022.
FDA. Guidance for industry: physicochemical and structural characterization of synthetic peptides. FDA; 2021.
23.
BerkowitzSAEngenJRMazzeoJR, et al.Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov2023; 22: 483–500.
24.
FDA. Draft guidance: drug products, including biological products, that contain nanomaterials. FDA, 2022.
25.
ZhengNSunDDZouP, et al.Scientific and regulatory considerations for generic complex drug products. Drug Discov Today2023; 28: 103518.
26.
FDA. Guidance for industry: Control of nitrosamine impurities in human drugs. FDA, 2023.
27.
SchlingemannJBurnsMJPontingDJ, et al.The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci2023; 112: 1287–1304. https://doi.org/10.1016/j.xphs.2022.11.013
28.
FDA. Updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities. FDA, 2023.
29.
BoetzelCBellamyCLCrossK, et al.A nitrite excipient database for evaluation of N-Nitrosamine risk. J Pharm Sci2023; 112: 1615–1624.
30.
FDA. Liquid Chromatography-High. Resolution mass spectrometry method for determination of nitrosamine impurities. FDA, 2023.
31.
CiocRCJoyceLADongMW. Recent advances in the analytical determination of N-Nitrosamines in pharmaceutical products. J Pharm Biomed Anal2023; 234: 115522.
FDA. Quality metrics site visit program for human drug manufacturing facilities. FDA, 2023.
50.
FDA. Guidance for industry: continuous manufacturing considerations for ANDAs. FDA, 2023.
51.
LeeSLO'ConnorTFYangX, et al.Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov2023; 18: 872–890.
52.
VanhoorneVVervaetC. Recent progress in continuous manufacturing of solid oral dosage forms. Int J Pharm2023; 643: 123213.
53.
FDA. Guidance for industry: changes to an approved application for specified biotechnology and synthetic biological products. FDA, 2023.
54.
FDA. Guidance for industry: comparability protocols for postapproval changes to the chemistry, manufacturing, and controls information in an ANDA. FDA, 2022.
55.
FDA. Guidance for industry: human factors studies and related clinical study considerations in combination product design and development. FDA, 2023.
56.
PriviteraMDWeltyTEGidalBE, et al.Generic-to-Generic lamotrigine switches in people with epilepsy. Lancet Neurol2023; 22: 585–598.
57.
FDA. Guidance for industry: statistical approaches to establishing bioequivalence. FDA, 2022.
58.
FDA. Guidance for industry: pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans. FDA, 2023.
59.
SalunkeSTuleuC. Formulating better pediatric medicines. Int J Pharm2023; 642: 123152.
FDA. Guidance for industry: Q8(R2) pharmaceutical development. FDA, 2023.
79.
YuLXAmidonGKhanMA, et al.Understanding pharmaceutical quality by design. AAPS J2023; 25: 7.
80.
RathoreASWinkleH. Quality by design for biopharmaceuticals: principles and case studies. Nat Biotechnol2023; 41: 21–32.
81.
FDA. Pharmaceutical quality/chemistry manufacturing and controls (PQ/CMC). FDA, 2023.
82.
FDA. Strategic plan for regulatory science. FDA, 2023.
83.
MeyerUAZangerUMSchwabM. Pharmacogenomics: from bench to byte. Nat Rev Drug Discov2023; 22: 879–896.
84.
FDA. Guidance for industry: clinical pharmacogenomics: premarket evaluation in early-phase clinical studies. FDA, 2023.
85.
FDA. Environmental assessment of human drug and biologics applications. FDA, 2023.
86.
AnastasPTZimmermanJB. The molecular basis of green chemistry. Science2023; 382: 1185–1189.
87.
FDA. Framework for FDA's real-world evidence program. FDA, 2023.
88.
ShermanREAndersonSADal PanGJ, et al.Real-world evidence — what is it and what can it tell us?N Engl J Med2023; 389: 2293–2297. https://doi.org/10.1056/NEJMsb1609216
89.
WoodcockJWosinskaM. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther2023; 113: 246–250.
90.
FDA. Annual report on drug shortages for calendar year 2023. FDA, 2024.
91.
FDA. Patient-focused drug development guidance series. FDA, 2023.
92.
FDA. Benefit-risk assessment for new drug and biological products. FDA, 2023.
